Your browser doesn't support javascript.
loading
How do I implement an outpatient program for the administration of convalescent plasma for COVID-19?
Bloch, Evan M; Tobian, Aaron A R; Shoham, Shmuel; Hanley, Daniel F; Gniadek, Thomas J; Cachay, Edward R; Meisenberg, Barry R; Kafka, Kimberly; Marshall, Christi; Heath, Sonya L; Shenoy, Aarthi; Paxton, James H; Levine, Adam; Forthal, Donald; Fukuta, Yuriko; Huaman, Moises A; Ziman, Alyssa; Adamski, Jill; Gerber, Jonathan; Cruser, Daniel; Kassaye, Seble G; Mosnaim, Giselle S; Patel, Bela; Metcalf, Ryan A; Anjan, Shweta; Reisler, Ronald B; Yarava, Anusha; Lane, Karen; McBee, Nichol; Gawad, Amy; Raval, Jay S; Zand, Martin; Abinante, Matthew; Broderick, Patrick B; Casadevall, Arturo; Sullivan, David; Gebo, Kelly A.
Afiliación
  • Bloch EM; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Tobian AAR; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Shoham S; Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Hanley DF; Department of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Gniadek TJ; Department of Pathology, Northshore University Health System, Evanston, Illinois, USA.
  • Cachay ER; Department of Medicine, Division of Infectious Diseases, University of California, San Diego, California, United States.
  • Meisenberg BR; Luminis Health, Annapolis, Maryland, USA.
  • Kafka K; Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Marshall C; Department of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Heath SL; Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Shenoy A; Department of Medicine, Division of Hematology and Oncology, Medstar Washington Hospital Center, Washington, District of Columbia, USA.
  • Paxton JH; Department of Emergency Medicine, Wayne State University, Detroit, Michigan, USA.
  • Levine A; Department of Emergency Medicine, Rhode Island Hospital/Brown University, Providence, Rhode Island, USA.
  • Forthal D; Department of Medicine, Division of Infectious Diseases, University of California, Irvine, California, United States.
  • Fukuta Y; Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, Texas, USA.
  • Huaman MA; Department of Medicine, Division of Infectious Diseases, University of Cincinnati, Cincinnati, Ohio, USA.
  • Ziman A; Department of Pathology, University of California, Los Angeles, California, USA.
  • Adamski J; Department of Laboratory Medicine, Mayo Clinic Hospital, Phoenix, Arizona, USA.
  • Gerber J; Department of Medicine, Division of Hematology and Oncology, University of Massachusetts, Worchester, Massachusetts, USA.
  • Cruser D; Nuvance Health Vassar Brothers Medical Center, Poughkeepsie, New York, USA.
  • Kassaye SG; Department of Medicine, Division of Infectious Diseases, Medstar Georgetown University Hospital, Washington, District of Columbia, USA.
  • Mosnaim GS; Division of Allergy and Immunology, Department of Medicine, Northshore University Health System, Evanston, Illinois, USA.
  • Patel B; Department of Medicine, Divisions of Pulmonary and Critical Care Medicine, University of Texas Health Science Center, Houston, Texas, USA.
  • Metcalf RA; Department of Medicine, Division of Infectious Diseases, University of Utah, Salt Lake City, Utah, USA.
  • Anjan S; Department of Medicine, Division of Infectious Diseases, University of Miami, Miller School of Medicine, Miami, Florida, USA.
  • Reisler RB; Davis Defense Group, Stafford, Virginia, USA.
  • Yarava A; Department of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Lane K; Department of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • McBee N; Department of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Gawad A; Department of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Raval JS; Department of Pathology, University of New Mexico, Albuquerque, New Mexico, USA.
  • Zand M; Department of Medicine, University of Rochester, Rochester, New York, USA.
  • Abinante M; Ascada Research, Fullerton, California, USA.
  • Broderick PB; Nuvance Health Danbury Hospital, Danbury, Connecticut, USA.
  • Casadevall A; Departments of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Sullivan D; Departments of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Gebo KA; Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Transfusion ; 62(5): 933-941, 2022 05.
Article en En | MEDLINE | ID: mdl-35352362
Convalescent plasma, collected from donors who have recovered from a pathogen of interest, has been used to treat infectious diseases, particularly in times of outbreak, when alternative therapies were unavailable. The COVID-19 pandemic revived interest in the use of convalescent plasma. Large observational studies and clinical trials that were executed during the pandemic provided insight into how to use convalescent plasma, whereby high levels of antibodies against the pathogen of interest and administration early within the time course of the disease are critical for optimal therapeutic effect. Several studies have shown outpatient administration of COVID-19 convalescent plasma (CCP) to be both safe and effective, preventing clinical progression in patients when administered within the first week of COVID-19. The United States Food and Drug Administration expanded its emergency use authorization (EUA) to allow for the administration of CCP in an outpatient setting in December 2021, at least for immunocompromised patients or those on immunosuppressive therapy. Outpatient transfusion of CCP and infusion of monoclonal antibody therapies for a highly transmissible infectious disease introduces nuanced challenges related to infection prevention. Drawing on our experiences with the clinical and research use of CCP, we describe the logistical considerations and workflow spanning procurement of qualified products, infrastructure, staffing, transfusion, and associated management of adverse events. The purpose of this description is to facilitate the efforts of others intent on establishing outpatient transfusion programs for CCP and other antibody-based therapies.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Observational_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Transfusion Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Observational_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Transfusion Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos